Response to Yu and Fuhler .
作者信息
Magahis Patrick Tiongco, Maron Steven B, Faleck David, Laszkowska Monika
机构信息
Weill Cornell Medical College of Cornell University, New York, New York, USA.
Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
出版信息
J Immunother Cancer. 2024 Jan 19;12(1):e008784. doi: 10.1136/jitc-2024-008784.
Abstract
摘要
相似文献
1
Response to Yu and Fuhler .
J Immunother Cancer. 2024 Jan 19;12(1):e008784. doi: 10.1136/jitc-2024-008784.
2
The Microbiome as a Component of the Tumor Microenvironment.
Adv Exp Med Biol. 2020;1225:137-153. doi: 10.1007/978-3-030-35727-6_10.
3
Retraction: "Safety limitations of fatty liver transplantation can be extended to 40%: Experience of a single centre in China", by Yu Z., Yu S., Zhang L., Feng X., Zhang M., et al.
Liver Int. 2017 May;37(5):767. doi: 10.1111/liv.13244. Epub 2016 Oct 13.
5
A response to Yu et al. "A forward-backward fragment assembling algorithm for the identification of genomic amplification and deletion breakpoints using high-density single nucleotide polymorphism (SNP) array", BMC Bioinformatics 2007, 8: 145.
BMC Bioinformatics. 2007 Oct 16;8:394. doi: 10.1186/1471-2105-8-394.
6
Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report.
J Immunother Cancer. 2023 Feb;11(2). doi: 10.1136/jitc-2022-006467.
7
Yu . 2019 is a later heterotypic synonym of On . 2019.
Int J Syst Evol Microbiol. 2024 Jun;74(6). doi: 10.1099/ijsem.0.006431.
8
Development and validation of a risk-prediction model for immune-related adverse events in patients with non-small-cell lung cancer receiving PD-1/PD-L1 inhibitors.
J Zhejiang Univ Sci B. 2023 Oct 15;24(10):935-942. doi: 10.1631/jzus.B2200631.
9
Correction for Yu et al., The NEDD8-activating enzyme inhibitor MLN4924 reduces ischemic brain injury in mice.
Proc Natl Acad Sci U S A. 2022 Dec 27;119(52):e2219262119. doi: 10.1073/pnas.2219262119. Epub 2022 Dec 19.
10
Response to " germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng.
J Immunother Cancer. 2023 Jun;11(6). doi: 10.1136/jitc-2023-007397.
本文引用的文献
1
Impact of infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors.
J Immunother Cancer. 2024 Jan 19;12(1):e008422. doi: 10.1136/jitc-2023-008422.
2
Impact of infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors.
J Immunother Cancer. 2023 Oct;11(10). doi: 10.1136/jitc-2023-007699.
3
Long-term Response of Helicobacter pylori Antibody Titer After Eradication Treatment in Middle-aged Japanese: JPHC-NEXT Study.
J Epidemiol. 2023 Jan 5;33(1):1-7. doi: 10.2188/jea.JE20200618. Epub 2021 Oct 19.
4
ACG and CAG Clinical Guideline: Management of Dyspepsia.
Am J Gastroenterol. 2017 Jul;112(7):988-1013. doi: 10.1038/ajg.2017.154. Epub 2017 Jun 20.
5
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
Am J Gastroenterol. 2017 Feb;112(2):212-239. doi: 10.1038/ajg.2016.563. Epub 2017 Jan 10.
6
American Gastroenterological Association medical position statement: evaluation of dyspepsia.
Gastroenterology. 2005 Nov;129(5):1753-5. doi: 10.1053/j.gastro.2005.09.019.
Zotero 插件